ArticleAnnals of medicine and surgery (2012)2025
Cardiovascular outcomes and safety assessment of SGLT2i on heart failure patients: a systematic review and meta-analysis.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sodium-glucose co-transporter 2 inhibitors (SGLT2is) are used in treating type 2 diabetes mellitus and show promise in improving outcomes in heart failure patients. This systematic review and meta-analysis aims to quantify the benefits and side effects of SGLT2i in heart failure patients with a reduced ejection fraction. Methods: A systematic search was conducted using PubMed, Cochrane Library, and Google Scholar with keywords such as "Sodium-Glucose Cotransporter 2 Inhibitor," "Myocardial Infarction," and "Cardiovascular." Inclusion criteria were randomized controlled trials involving patients with heart failure. Primary outcomes were hospitalization due to heart failure and cardiovascular mortality. Secondary outcomes included discontinuation due to adverse effects, amputation, fractures, and urinary tract infections. Results: Eight randomized controlled trials were included. The interventional group showed significantly lower hospitalizations ( Conclusion: SGLT2 inhibitors, due to their natriuretic, cardio-metabolic, and vaso-modulatory effects, offer a promising role in reducing cardiovascular complications in patients with type 2 diabetes mellitus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.